
    
      The purpose of this study is

        1. to monitor short children born SGA who were treated with growth hormone in study
           EP00-401 for the development of diabetes for a further 10 years after termination of
           growth hormone treatment

           and

        2. to report the incidence of anti-rhGH antibodies and of E. coli host cell peptide (HCP)
           antibodies (ABs) for 6 months after termination of GH treatment.
    
  